ARF1-related disorder: phenotypic and molecular spectrum - PubMed (original) (raw)

. 2023 Oct;60(10):999-1005.

doi: 10.1136/jmg-2022-108803. Epub 2023 Apr 25.

Ben Pode-Shakked 2 3, Sophie Naudion 4, Vincent Michaud 4 5, Benoit Arveiler 4 5, Patricia Fergelot 4 5, Jean Delmas 6, Boris Keren 7, Céline Poirsier 8, Fowzan S Alkuraya 9, Brahim Tabarki 10, Eric Bend 11, Kellie Davis 12, Martina Bebin 13, Michelle L Thompson 14, Emily M Bryant 15, Matias Wagner 16 17, Iris Hannibal 18, Jerica Lenberg 19, Martin Krenn 20, Kristen M Wigby 21, Jennifer R Friedman 22 23, Maria Iascone 24, Anna Cereda 25, Térence Miao 7 26, Eric LeGuern 7 27, Emanuela Argilli 28, Elliott Sherr 28, Oana Caluseriu 29, Timothy Tidwell 30, Pinar Bayrak-Toydemir 31, Caroline Hagedorn 32, Melanie Brugger 33, Katharina Vill 34, Francois-Dominique Morneau-Jacob 35, Wendy Chung 36, Kathryn N Weaver 2, Joshua W Owens 2, Ammar Husami 2, Bimal P Chaudhari 37 38 39, Brandon S Stone 40, Katie Burns 41, Rachel Li 42, Iris M de Lange 43, Margaux Biehler 44, Emmanuelle Ginglinger 45, Bénédicte Gérard 44, Rolf W Stottmann 2 46, Aurélien Trimouille 4 5 47

Affiliations

_ARF1_-related disorder: phenotypic and molecular spectrum

Jean-Madeleine de Sainte Agathe et al. J Med Genet. 2023 Oct.

Abstract

Purpose: ARF1 was previously implicated in periventricular nodular heterotopia (PVNH) in only five individuals and systematic clinical characterisation was not available. The aim of this study is to provide a comprehensive description of the phenotypic and genotypic spectrum of _ARF1_-related neurodevelopmental disorder.

Methods: We collected detailed phenotypes of an international cohort of individuals (n=17) with ARF1 variants assembled through the GeneMatcher platform. Missense variants were structurally modelled, and the impact of several were functionally validated.

Results: De novo variants (10 missense, 1 frameshift, 1 splice altering resulting in 9 residues insertion) in ARF1 were identified among 17 unrelated individuals. Detailed phenotypes included intellectual disability (ID), microcephaly, seizures and PVNH. No specific facial characteristics were consistent across all cases, however microretrognathia was common. Various hearing and visual defects were recurrent, and interestingly, some inflammatory features were reported. MRI of the brain frequently showed abnormalities consistent with a neuronal migration disorder.

Conclusion: We confirm the role of ARF1 in an autosomal dominant syndrome with a phenotypic spectrum including severe ID, microcephaly, seizures and PVNH due to impaired neuronal migration.

Keywords: epilepsy; human genetics; sequence analysis, DNA.

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1

Figure 1

Clinical overview of 21 individuals with ARF1 variants (17 individuals from this study, 3 individuals previously reported from Ge et al and one from Gana et al. Tolerance landscape from MetaDome. Plain lines point to the missense location, dashed lines point to non-missense altered residues (either to the premature terminating codon or to the nine residues insertion).

Figure 2

Figure 2

(A) Locations of the eight residues (yellow) altered in the two conformations of ARF1. Left, ARF1 in its inactive conformation from 1r8q; right, ARF1 in active conformation from 6cm9; blue chain: ARF1; grey chain: ARFGEF sec7 domain. Images created using Mol*. (B, C) Deleterious effect of patient ARF1 variants on nucleotide activation. Comparison of ARF1 nucleotide activation in lysates of 293 T cells transfected with either the wild-type (WT) ARF1 plasmid or that harbouring one of the five variants (p.Tyr35His, p.Thr48Ile, p.Phe51Leu, p.Arg99His, p.Lys127Glu). Lane 1, basal activated ARF1 in 293 T cells without plasmid transfection. Pulldown for GTP-activated ARF1 in cells transfected with WT (lane 2) vs patient variant-containing ARF1 plasmid (lanes 3–7). ARF1 band is visible at 21 kDa. Western blot analysis results are representative of three independent transfection and pulldown experiments. (C) Quantification of relative nucleotide activation in lysates of 293 T cells transfected with ARF1 plasmids harbouring one of five patient ARF1 variants compared with a WT ARF1 and no plasmid. Mean results are presented as the mean (±SEM) of three separate experiments. P value of the result of each variant in comparison to the WT is presented.

References

    1. Guerrini R, Dobyns WB. Malformations of cortical development: clinical features and genetic causes. Lancet Neurol 2014;13:710–26. 10.1016/S1474-4422(14)70040-7 -DOI -PMC -PubMed
    1. Lian G, Sheen VL. Cytoskeletal proteins in cortical development and disease: actin associated proteins in periventricular heterotopia. Front Cell Neurosci 2015;9:99. 10.3389/fncel.2015.00099 -DOI -PMC -PubMed
    1. Liu Y, Kahn RA, Prestegard JH. Structure and membrane interaction of myristoylated ARF1. Structure 2009;17:79–87. 10.1016/j.str.2008.10.020 -DOI -PMC -PubMed
    1. Beck R, Prinz S, Diestelkötter-Bachert P, et al. Coatomer and dimeric ADP ribosylation factor 1 promote distinct steps in membrane scission. J Cell Biol 2011;194:765–77. 10.1083/jcb.201011027 -DOI -PMC -PubMed
    1. Ge X, Gong H, Dumas K, et al. Missense-depleted regions in population exomes implicate ras superfamily nucleotide-binding protein alteration in patients with brain malformation. Npj Genomic Med 2016;1. 10.1038/npjgenmed.2016.36 -DOI -PMC -PubMed

MeSH terms

Substances

LinkOut - more resources